<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04109820</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY18120144</org_study_id>
    <nct_id>NCT04109820</nct_id>
  </id_info>
  <brief_title>Effect of MitoQ on Platelet Function and Reactive Oxygen Species Generation in Patients With Sickle Cell Anemia</brief_title>
  <acronym>MitoQ</acronym>
  <official_title>Effect of MitoQ on Platelet Function and Reactive Oxygen Species (ROS) Generation in Patients With Sickle Cell Anemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      MitoQ is commercially available as a dietary supplement and it has been tested as a potential
      drug in other diseases, but it has never been tested in patients with sickle cell disease.

      The goal of this research is to study if MitoQ, a molecule that works as an antioxidant by
      removing potentially damaging agents in a living organism, improves platelet function in
      patients with sickle cell disease (SCD).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antioxidant therapies targeted to specific enzymes or compartments may be beneficial in
      sickle cell anemia (SCA). MitoQ, the most extensively studied mitochondrial-targeted
      antioxidant, has been shown to be protective against ischemia/reperfusion injury in the
      heart, endothelial damage due to hypertension and ROS in animal models. MitoQ is commercially
      available as a dietary supplement to reduce overall oxidative stress and anti-ageing.
      However, MitoQ has not been tested either as a platelet antagonist or as an endothelial
      protectant in SCA patients. Investigators propose to conduct a small clinical trial of MitoQ
      in subjects with SCA to test the hypothesis that MitoQ scavenges platelet mtROS to prevent
      platelet activation and attenuate vascular dysfunction in SCA.

      Investigators will test whether MitoQ decreases basal platelet activation in SCD patients and
      attenuates vascular dysfunction in subjects with SCA. Investigators will administer MitoQ
      orally to patients and healthy controls for 14 days. Investigators will obtain platelet
      count, hemolytic markers, platelet mtROS levels and activation markers, clinic BP
      measurements before and after MitoQ.

      Adult male and female SCA subjects in steady state (n=10) and 5 healthy African-American
      volunteers will be recruited after obtaining informed consent.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Non randomized case control study design.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of MitoQ on platelet activation markers in subjects with SCA</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>Change in the percentage of platelet activation markers in blood will be measured (p-selectin, activated GpIIb/IIIa expression, platelet mtROS [mitochondrial reactive oxygen species], platelet bioenergetics, mitochondrial Complex V activity)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of MitoQ on vascular dysfunction in subjects with SCA</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>Changes in both systolic and diastolic blood pressure will be measured during the study period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of MitoQ on hemolysis in subjects with SCA</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>Changes in plasma free hemoglobin level (mg/dL) will be measured in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of MitoQ on hemolysis in subjects with SCA</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>Changes in plasma adenosine diphosphate level (micromole/liter) will be measured in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of MitoQ on hemolysis in subjects with SCA</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>Changes in serum lactate dehydrogenase level (units/L) will be measured in blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related severe adverse events (SAE)</measure>
    <time_frame>Baseline to 14 days</time_frame>
    <description>Overall incidence of treatment emergent severe adverse events (SAE)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Sickle cell patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sickle Cell subjects administered oral MitoQ (20mg once a day for 14 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Sickle cell Control subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Normal control subjects administered oral MitoQ (20mg once a day for 14 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>MitoQ</intervention_name>
    <description>Oral; 20mg once a day for 14 days</description>
    <arm_group_label>Non Sickle cell Control subjects</arm_group_label>
    <arm_group_label>Sickle cell patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects

          -  African American

          -  Patients with sickle cell anemia

          -  18 years old or older

        Control

          -  African American healthy controls

          -  18 years of age or older

        Exclusion Criteria:

          1. Pregnancy,

          2. Known hypertension,

          3. Hemodialysis and active obstructive sleep apnea requiring treatment.

          4. Use of anti-platelet medication or have had transfusion in the 4 weeks prior to
             enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramasubramanian Kalpatthi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mikhil N Bamne, PhD</last_name>
    <phone>(412) 648-6920</phone>
    <email>bamnemn2@upmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jude Jonassaint, RN</last_name>
    <phone>412-692-2086</phone>
    <email>jonassaintjc@upmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Magee Women's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhil N Bamne, PhD</last_name>
      <phone>412-648-6920</phone>
      <email>bamnemn2@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jude Jonassaint, RN</last_name>
      <phone>412-692-2086</phone>
      <email>jonassaintjc@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ramasubramanian Kalpatthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Montefiore</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhil N Bamne, PhD</last_name>
      <phone>412-648-6920</phone>
      <email>bamnemn2@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jude Jonassaint, RN</last_name>
      <phone>412-692-2086</phone>
      <email>jonassaintjc@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ramasubramanian Kalpatthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UPMC Presbyterian</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhil N Bamne, PhD</last_name>
      <phone>412-648-6920</phone>
      <email>bamnemn2@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jude Jonassaint, RN</last_name>
      <phone>(412) 692-2086</phone>
      <email>jonassaintjc@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ramasubramanian Kalpatthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhil N Bamne, PhD</last_name>
      <phone>412-648-6920</phone>
      <email>bamnemn2@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jude Jonassaint, RN</last_name>
      <phone>(412) 692-2086</phone>
      <email>jonassaintjc@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ramasubramanian Kalpatthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillman Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mikhil N Bamne, PhD</last_name>
      <phone>412-648-6920</phone>
      <email>bamnemn2@upmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jude Jonassaint, RN</last_name>
      <phone>412-692-2086</phone>
      <email>jonassaintjc@upmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ramasubramanian Kalpatthi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>September 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 30, 2019</study_first_posted>
  <last_update_submitted>April 3, 2020</last_update_submitted>
  <last_update_submitted_qc>April 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Ramasubramanian Kalpatthi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Basal platelet activation</keyword>
  <keyword>MitoQ</keyword>
  <keyword>mitochondrial ROS (Reactive Oxygen Species)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The investigators may share de-identified data with others who are doing similar types of research. All collected individual participant data (IPD), all IPD that underlie results in a publication will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data will be available 6 months after the publication. July 2022.</ipd_time_frame>
    <ipd_access_criteria>The IPD and any additional supporting information will be shared, with other investigators/collaborators when requested. The Principal Investigator will review the requests and will provide the instructions to the research site staff to share the IPD with other investigators.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

